Experienced in X-Linked Lymphoproliferative Disease

Jan-inge I. Henter

Stockholm, AB, SE 
Experienced in X-Linked Lymphoproliferative Disease
Stockholm, AB, SE 
OverviewLocationsClinical Research

Overview

Jan-inge Henter practices in Stockholm, Sweden. Henter is rated as an Experienced expert by MediFind in the treatment of X-Linked Lymphoproliferative Disease. Their top areas of expertise are Hemophagocytic Lymphohistiocytosis, Reticulohistiocytoma, Histiocytosis, Non-Langerhans-Cell Histiocytosis, and Bone Marrow Transplant.

Their clinical research consists of co-authoring 120 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 1 article in the study of X-Linked Lymphoproliferative Disease.

Locations

Stockholm, AB, Sweden
Other Locations
Solna, AB, Sweden
Huddinge, AB, Sweden

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase 2/3 Open-label Single Arm Multicentre Study to Assess Safety Tolerability Pharmacokinetics and Efficacy of i.v. Administrations of NI-0501 an Anti-IFNγ mAb in Paediatric Patients With Primary Haemophagocytic Lymphohistiocytosis
A Phase 2/3 Open-label Single Arm Multicentre Study to Assess Safety Tolerability Pharmacokinetics and Efficacy of i.v. Administrations of NI-0501 an Anti-IFNγ mAb in Paediatric Patients With Primary Haemophagocytic Lymphohistiocytosis
Enrollment Status: Completed
Publish Date: February 21, 2023
Intervention Type: Biological
Study Phase: Phase 2/Phase 3
A Multicenter Study for the Long-term Follow-up of HLH Patients Who Received Treatment With NI-0501, an Anti-interferon Gamma Monoclonal Antibody
A Multicenter Study for the Long-term Follow-up of HLH Patients Who Received Treatment With NI-0501, an Anti-interferon Gamma Monoclonal Antibody
Enrollment Status: Completed
Publish Date: June 28, 2022
Intervention Type: Drug
Study Phase: Phase 2/Phase 3
View 1 Less Clinical Trial

120 Total Publications

Erratum to <[Transplant Cell Ther. 2023 Jul;29(7):438.e1-438.e16. Epub 2023 Mar 9]>.
Erratum to <[Transplant Cell Ther. 2023 Jul;29(7):438.e1-438.e16. Epub 2023 Mar 9]>.
Journal: Transplantation and cellular therapy
Published: October 09, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Henter's expertise for a condition
ConditionClose
View All 7 Advanced Conditions
View All 40 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile